CJH Stock Overview
Develops, manufactures, and commercializes vaccines in the People’s Republic of China. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
CanSino Biologics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$3.92 |
52 Week High | HK$4.22 |
52 Week Low | HK$1.81 |
Beta | 0.46 |
11 Month Change | 18.07% |
3 Month Change | 90.29% |
1 Year Change | 44.06% |
33 Year Change | -78.07% |
5 Year Change | -28.73% |
Change since IPO | 12.64% |
Recent News & Updates
Recent updates
Shareholder Returns
CJH | DE Biotechs | DE Market | |
---|---|---|---|
7D | 18.1% | 1.5% | 3.2% |
1Y | 44.1% | -14.5% | 9.7% |
Return vs Industry: CJH exceeded the German Biotechs industry which returned -13.9% over the past year.
Return vs Market: CJH exceeded the German Market which returned 10.1% over the past year.
Price Volatility
CJH volatility | |
---|---|
CJH Average Weekly Movement | 14.1% |
Biotechs Industry Average Movement | 6.8% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 11.5% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CJH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CJH's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 1,149 | Xuefeng Yu | www.cansinotech.com |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
CanSino Biologics Inc. Fundamentals Summary
CJH fundamental statistics | |
---|---|
Market cap | €1.58b |
Earnings (TTM) | -€93.78m |
Revenue (TTM) | €97.48m |
10.2x
P/S Ratio-10.6x
P/E RatioIs CJH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CJH income statement (TTM) | |
---|---|
Revenue | CN¥748.53m |
Cost of Revenue | CN¥774.40m |
Gross Profit | -CN¥25.87m |
Other Expenses | CN¥694.25m |
Earnings | -CN¥720.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.91 |
Gross Margin | -3.46% |
Net Profit Margin | -96.20% |
Debt/Equity Ratio | 41.3% |
How did CJH perform over the long term?
See historical performance and comparison